10mg/ tab, 100tabs
Oxandrolone tablet contains 10 mg of oxandrolone. Oxandrolone is stable in air, but darkens on exposure to light. Melts at about 225°C. Practically insoluble in water; freely soluble in chloroform; sparingly soluble in alcohol and in acetone.
In a single dose pharmacokinetic study of oxandrolone in elderly subjects, the mean elimination half-life was 13.3 hours. In a previous single dose pharmacokinetic study in younger volunteers, the mean elimination half-life was 10.4 hours. No significant differences between younger and elderly volunteers were found for peak time, peak plasma concentration or AUC after a single dose of oxandrolone. The correlation between plasma level and therapeutic effect has not been defined.
Indications and Usage
Indications of oxandrolone as adjunctive therapy are to promote weight gain after weight loss following extensive surgery, chronic infections, or severe trauma and in some patients who fail to gain or maintain normal weight without definite pathophysiologic reasons, to offset the protein catabolism associated with prolonged administration of corticosteroids, and to relief osteoporosis bone pain.
Therapy with anabolic steroids is adjunctive to and not a replacement for conventional therapy. The duration of oxandrolone therapy depends on the response of a patient and appearance of adverse reactions. Therapy should be intermittent. Adults-The response of individuals to anabolic steroids varies.
The daily adult dosage is 2.5 mg to 20 mg given in 2-4 divided doses. The desired response can be achieved with as little as 2.5 mg or as much as 20mg daily. A 2-4 weeks therapy course is usually adequate. A course can be repeated if indicated. Children- the total daily dose of oxandrolone for children is 0.1 mg per kilogram of body weight. A course can be repeated if indicated. Geriatric Use-Recommended dose for geriatric patients is 5 mg.
Cholestatic hepatitis and jaundice may occur with 17-alpha-alkylated androgens at a relatively low dose. If cholestatic hepatitis with jaundice appears or liver function tests become abnormal, oxandrolone should be discontinued and the etiology should be determined. Drug-induced jaundice is reversible when the medication is discontinued. In patients with breast cancer, anabolic steroid therapy may cause hypercalcemia by stimulating osteolysis. Oxandrolone therapy should be discontinued if hypercalcemia occurs. Edema with or without congestive heart failure is a serious complication in patients with pre-existing cardiac, renal, or hepatic disease. Concomitant administration of corticosteroids or ACTH may increase the edema. In children, androgen therapy may accelerate bone maturation without producing compensatory gain in linear growth. This adverse effect results in compromised adult height. The younger the child, the greater the risk of compromising final mature height. The effect on bone maturation should be Geriatric male patients treated with androgenic anabolic steroids
may be at an increased risk for the development of prostate hypertrophy and prostatic carcinoma.
Anabolic steroids may increase sensitivity to oral anticoagulants. Dosage of the anticoagulant may have to be adjusted in order to maintain the prothrombin time at the desired therapeutic level. Patients receiving oral anticoagulant therapy require close monitoring, especially when starting or stopping taking anabolic steroids.
Oral Anticoagulants (blood thinners). Stanozolol enhances effects of anticoagulants and thus causes excessive bleeding.
Oral hypoglycemic agent and insulin. Stanozolol can decrease blood sugar level and insulin in diabetic patients. Corticosteroids. Tendency towards edema is enhanced, use with caution in patients with hepatic or cardiac disease. Enzyme-inducing agents may increase or decrease testosterone levels Therefore, adjustment of the dose, and/or intervals between administrations may be required. Caution should be taken when administering Stanozolol to patients with a history of myocardial infarction or coronary artery disease as androgens may alter serum cholesterol concentrations.
Hepatic Hepatocellular neoplasms have been reported in association with long-term androgenic anabolic steroid therapy.
Prepubertal: Phallic enlargement and increased frequency of erections.
Postpubertal: Inhibition of testicular function, testicular atrophy and oligospermia, impotence, chronic priapism, epididymitis and bladder irritation.
Clitoral enlargement, menstrual irregularities.
In both genders: Increased or decreased libido.
CNS: Habituation, excitation, insomnia, depression.
Gastrointestinal: Nausea, vomiting, diarrhea.
Hematologic: Bleeding in patients on concomitant anticoagulant therapy
Larynx: Deepening of the voice in women.
Hair: Hirsutism and male pattern of baldness in women.
Skin: Acne (especially in women and prepubertal boys.)
Fluid and Electrolytes: Edema, retention of serum electrolytes (sodium, chloride, potassium, phosphate, calcium). Metabolic/Endocrine: Decreased glucose tolerance, increased serum levels of low-density lipoprotein and decreased levels of high-density lipoprotein, increased creatine and creatinine excretion, increased serum levels of creatinine phosphokinase (CPK).
Some virilizing changes in women are irreversible even after prompt discontinuance of therapy and are not prevented by concomitant use of estrogens.
There have been no reports of acute overdosing with this substance. Symptomatic treatment should be provided
Store in a dark, dry place. Keep away from children.
Tablet in vial, or pvc-alu blisters